Sp eci al t y Dr u g M an agem en t : Wh at You M u st K n ow Brenda Motheral, RPh, MBA, PhD CEO, Archimedes ©© AARRCCHHIIMMEEDDEESS 22001188 Confidential and Proprietary 2 Specialty Drug Forecast Across Pharmacy and Medical The Specialty Challenge $1,147 • Price, Price, Price $1,026 $915 $811 • Siloed vendors $722 • Lack of cost transparency • Overprescribing and questions of value • Vendor conflicts of interest 2016 2017 2018 2019 2020 © ARCHIMEDES 2018 Confidential and Proprietary 3 H.P. Acthar Pricing Drug Pricing Is Receiving Scrutiny Lifetime limits on coverage removed by ACA Source: Truven. Accessed at https://amp.businessinsider.com/drug-price-gouging-explained-on-baml- conference-call-2017- © ARCHIMEDES 2018 Confidential and Proprietary 12?utm_source=hearst&utm_medium=referral&utm_content=allverticals&__twitter_impression=true The Coverage Conundrum Duplicate claims, Benefit shopping, Inappropriate use and site of care 4 © ARCHIMEDES 2018 Confidential and Proprietary 5 Duplicate Billing © ARCHIMEDES 2018 Confidential and Proprietary Rem icade Cost by Channel (600 mg Infusion) 6 © ARCHIMEDES 2018 Confidential and Proprietary 7 The Value of Specialty Drugs is in Question ▫ Many cancer drugs are approved by the FDA based on surrogate end points ▫ 86% of these cancer drugs did NOT lengthen patients lives after 4+ years on the market Source:Chambers et al. Health Affairs. 2014., Kim and Prasad. JAMA. 2016. Source: Kim and Prasad, JAMA, 2015. © ARCHIMEDES 2018 Confidential and Proprietary PBM Conflicts of Interest Formularies are Rebate-Driven PA Programs are Ineffective Stockpiling 8 © ARCHIMEDES 2018 Confidential and Proprietary 9 Overall Specialty Spend © ARCHIMEDES 2018 Confidential and Proprietary 10 Specialty Drug Savings © ARCHIMEDES 2018
Description: